Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Here is how Catalyst Pharmaceutical (CPRX) and Lyell Immunopharma (LYEL) have performed compared to their sector so far this year.

Is Catalyst Pharmaceuticals (CPRX) Outperforming Other Medical Stocks This Year?

Catalyst Pharmaceuticals reached a 52-week high on September 13, 2022. Catalyst was recently added to the S&P SmallCap 600 Index.

Catalyst Pharmaceuticals Ramp May Be Over For Now

Albemarle

Some companies can stand up to tough conditions on Wall Street.

As Markets Plunged, These 2 Stocks Hit All-Time Highs

Teekay Tankers

Both are in buy zones after topping follow-on patterns. The post Biotech, Tanker Stocks Hit New Highs, Top Bullish Patterns appeared first on Investor's Business Daily.

Biotech, Tanker Stocks Hit New Highs, Top Bullish Patterns

This supercharged growth stock posted a new all-time high this week.

Why Catalyst Pharmaceuticals Stock Marched Higher This Week

AVEO Pharma

Tsakos Energy Navigation Limited

Tsakos Energy Navigation (TNP), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX) have been selected as the breakout stocks for today.

Buy These 3 Top Breakout Stocks Now for Superb Returns

CORAL GABLES, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate in the hybrid in-person and virtual H.C. Wainwright 24th Annual Global Investment Conference being held on September 12-14, 2022.

Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?

Pharmaceuticals stock is trading above a 3-week base on heavy volume. The company is first in its industry.

Pharmaceuticals Stock Clears A Base Following Two Prior Gap-Ups

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Catalyst Pharmaceutical (CPRX) Just Reclaimed the 20-Day Moving Average

Veru

Their recent successes with commercializing medicines are paying off.

Got $1,500? Buy These 2 Surging Growth Stocks

Catalyst Pharmaceuticals is now looking for its second act after launching a LEMS treatment. Could CPRX stock investors see a buyout?

Catalyst Pharmaceuticals' CEO Wants In On The Biotech Buying Spree

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Catalyst (CPRX) Is a Great Growth Stock

Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock to Buy

CORAL GABLES, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Citi's 17th Annual BioPharma Conference.

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

It might not last forever, but for now they're preparing to grow aggressively.

Got $2,500? These 2 Small-Cap Monsters Are Crushing Tesla Stock

Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.

Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up

Start Time: 08:30 January 1, 0000 9:12 AM ET Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2022 Earnings Conference Call August 10, 2022, 08:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman, President and CEO Jeff Del Carmen - Chief Commercial Officer Steven Miller - COO and Chief Scientific Officer Ali Grande - VP, CFO and Treasurer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joe Catanzaro - Piper Sandler Les Sulewski - Truist Securities Operator Greetings, and welcome to the Catalyst Pharmaceuticals Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2022 Results - Earnings Call Transcript

Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates

Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.

Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why

Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?

Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.

Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug

As Part of the Settlement, Catalyst has Acquired Certain of Jacobus' Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi® As Part of the Settlement, Catalyst has Acquired Certain of Jacobus' Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi®

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

News for Catalyst Pharmaceuticals Stock (CPRX)